Trait Information | |
Identifier | MONDO_0002898 |
Description | A malignant neoplasm involving the zone of skin | Trait category |
Cancer
|
Synonyms |
19 synonyms
|
Mapped terms |
8 mapped terms
|
Child trait(s) | 6 child traits |
Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants |
Ancestry distribution GWAS Dev Eval |
Scoring File (FTP Link) |
---|---|---|---|---|---|---|
PGS000119 (BCC32) |
PGP000055 | Fritsche LG et al. PLoS Genet (2019) |
Basal cell carcinoma | basal cell carcinoma | 32 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000119/ScoringFiles/PGS000119.txt.gz |
PGS000339 (PRS22_CM) |
PGP000106 | Law MH et al. Hum Mol Genet (2020) |
Cutaneous melanoma | cutaneous melanoma | 22 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000339/ScoringFiles/PGS000339.txt.gz | |
PGS000398 (PRSWEB_PHECODE172_20001-1003_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 1,103,220 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000398/ScoringFiles/PGS000398.txt.gz | |
PGS000399 (PRSWEB_PHECODE172_20001-1003_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 6 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000399/ScoringFiles/PGS000399.txt.gz | |
PGS000400 (PRSWEB_PHECODE172_C3-SKIN_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 95 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000400/ScoringFiles/PGS000400.txt.gz | |
PGS000401 (PRSWEB_PHECODE172_C3-SKIN_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 1,111,490 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000401/ScoringFiles/PGS000401.txt.gz | |
PGS000402 (PRSWEB_PHECODE172_C3-SKIN_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 389 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000402/ScoringFiles/PGS000402.txt.gz | |
PGS000403 (PRSWEB_PHECODE172_C3-SKIN_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 16,316 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000403/ScoringFiles/PGS000403.txt.gz | |
PGS000404 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 80 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000404/ScoringFiles/PGS000404.txt.gz | |
PGS000405 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000405/ScoringFiles/PGS000405.txt.gz | |
PGS000406 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 292 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000406/ScoringFiles/PGS000406.txt.gz | |
PGS000407 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Skin cancer | skin carcinoma | 3,166 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000407/ScoringFiles/PGS000407.txt.gz | |
PGS000433 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 108 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000433/ScoringFiles/PGS000433.txt.gz | |
PGS000434 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 1,111,490 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000434/ScoringFiles/PGS000434.txt.gz | |
PGS000435 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 446 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000435/ScoringFiles/PGS000435.txt.gz | |
PGS000436 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 16,626 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000436/ScoringFiles/PGS000436.txt.gz | |
PGS000437 (PRSWEB_PHECODE172.2_C44_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 63 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000437/ScoringFiles/PGS000437.txt.gz | |
PGS000438 (PRSWEB_PHECODE172.2_C44_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 1,111,490 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000438/ScoringFiles/PGS000438.txt.gz | |
PGS000439 (PRSWEB_PHECODE172.2_C44_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 467 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000439/ScoringFiles/PGS000439.txt.gz | |
PGS000440 (PRSWEB_PHECODE172.2_C44_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 2,111 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000440/ScoringFiles/PGS000440.txt.gz | |
PGS000441 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 77 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000441/ScoringFiles/PGS000441.txt.gz | |
PGS000442 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000442/ScoringFiles/PGS000442.txt.gz | |
PGS000443 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 177 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000443/ScoringFiles/PGS000443.txt.gz | |
PGS000444 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Other non-epithelial skin cancer | skin cancer | 7,231 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000444/ScoringFiles/PGS000444.txt.gz | |
PGS000445 (PRSWEB_PHECODE172.21_20001-1061_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 19 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000445/ScoringFiles/PGS000445.txt.gz | |
PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 1,111,490 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000446/ScoringFiles/PGS000446.txt.gz | |
PGS000447 (PRSWEB_PHECODE172.21_20001-1061_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 72 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000447/ScoringFiles/PGS000447.txt.gz | |
PGS000448 (PRSWEB_PHECODE172.21_20001-1061_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 183 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000448/ScoringFiles/PGS000448.txt.gz | |
PGS000449 (PRSWEB_PHECODE172.21_20001-1073_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 1,073,162 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000449/ScoringFiles/PGS000449.txt.gz | |
PGS000450 (PRSWEB_PHECODE172.21_20001-1073_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 8 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000450/ScoringFiles/PGS000450.txt.gz | |
PGS000451 (PRSWEB_PHECODE172.21_20001-1073_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 2,231 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000451/ScoringFiles/PGS000451.txt.gz | |
PGS000452 (PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 28 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000452/ScoringFiles/PGS000452.txt.gz | |
PGS000453 (PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 28 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000453/ScoringFiles/PGS000453.txt.gz | |
PGS000454 (PRSWEB_PHECODE172.21_BCC-Chahal_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 27 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000454/ScoringFiles/PGS000454.txt.gz | |
PGS000455 (PRSWEB_PHECODE172.21_BCC-Chahal_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 28 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000455/ScoringFiles/PGS000455.txt.gz | |
PGS000456 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 30 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000456/ScoringFiles/PGS000456.txt.gz | |
PGS000457 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 30 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000457/ScoringFiles/PGS000457.txt.gz | |
PGS000458 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 23 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000458/ScoringFiles/PGS000458.txt.gz | |
PGS000459 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Basal cell carcinoma | basal cell carcinoma | 24 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000459/ScoringFiles/PGS000459.txt.gz | |
PGS000469 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Carcinoma in situ of skin | skin carcinoma in situ | 1,119,238 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000469/ScoringFiles/PGS000469.txt.gz | |
PGS000470 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Carcinoma in situ of skin | skin carcinoma in situ | 5 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000470/ScoringFiles/PGS000470.txt.gz | |
PGS000471 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Carcinoma in situ of skin | skin carcinoma in situ | 7 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000471/ScoringFiles/PGS000471.txt.gz | |
PGS000730 (PRS_BCC) |
PGP000138 | Fontanillas P et al. Nat Commun (2021) |
Basal cell carcinoma | basal cell carcinoma | 47 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000730/ScoringFiles/PGS000730.txt.gz |
PGS000766 (PRS56_CM) |
PGP000172 | Bakshi A et al. J Natl Cancer Inst (2021) |
Cutaneous melanoma | cutaneous melanoma | 56 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000766/ScoringFiles/PGS000766.txt.gz |
PGS001040 (GBE_cancer1060) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Non melanoma skin cancer | non-melanoma skin carcinoma | 1,610 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001040/ScoringFiles/PGS001040.txt.gz |
PGS001041 (GBE_cancer1003) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Skin cancer | skin carcinoma | 1,298 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001041/ScoringFiles/PGS001041.txt.gz |
PGS001803 (portability-PLR_172) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Skin cancer | skin carcinoma | 4,371 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001803/ScoringFiles/PGS001803.txt.gz |
PGS002014 (portability-ldpred2_172) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Skin cancer | skin carcinoma | 534,399 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002014/ScoringFiles/PGS002014.txt.gz |
PGS003382 (best_SKCM) |
PGP000413 | Namba S et al. Cancer Res (2022) |
Skin cutaneous melanoma | cutaneous melanoma | 672 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003382/ScoringFiles/PGS003382.txt.gz |
PGS003416 (MTAGPRS) |
PGP000429 | Seviiri M et al. Nat Commun (2022) |
Basal cell carcinoma (MTAG) | basal cell carcinoma | 462 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003416/ScoringFiles/PGS003416.txt.gz |
PGS003417 (UKBPRS) |
PGP000429 | Seviiri M et al. Nat Commun (2022) |
Basal cell carcinoma | basal cell carcinoma | 273 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003417/ScoringFiles/PGS003417.txt.gz |
PGS003745 (PRS57_SM) |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Skin Melanoma | cutaneous melanoma | 57 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003745/ScoringFiles/PGS003745.txt.gz | |
PGS004247 (PRS65_melanoma) |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Melanoma | cutaneous melanoma | 65 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004247/ScoringFiles/PGS004247.txt.gz |
PGS004592 (PRS_KC) |
PGP000571 | Liyanage UE et al. J Eur Acad Dermatol Venereol (2022) |
Keratinocyte cancer | keratinocyte carcinoma | 78 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004592/ScoringFiles/PGS004592.txt.gz |
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|---|
PPM000344 | PGS000119 (BCC32) |
PSS000207| European Ancestry| 20,468 individuals |
PGP000055 | Fritsche LG et al. PLoS Genet (2019) |
Reported Trait: Skin cancer | OR: 1.32 [1.27, 1.36] | AUROC: 0.58 [0.56, 0.58] | — | age, sex, batch, PC1-4 | — |
PPM000341 | PGS000119 (BCC32) |
PSS000209| European Ancestry| 20,468 individuals |
PGP000055 | Fritsche LG et al. PLoS Genet (2019) |
Reported Trait: Basal cell carcinoma | OR: 1.65 [1.56, 1.75] | AUROC: 0.64 [0.62, 0.66] | — | age, sex, batch, PC1-4 | — |
PPM000347 | PGS000119 (BCC32) |
PSS000211| European Ancestry| 149,857 individuals |
PGP000055 | Fritsche LG et al. PLoS Genet (2019) |
Reported Trait: Skin cancer | OR: 1.4 [1.42, 1.48] | — | — | age, sex, genotyping array, first 4 genotype PCs | — |
PPM000922 | PGS000339 (PRS22_CM) |
PSS000464| European Ancestry| 1,885 individuals |
PGP000106 | Law MH et al. Hum Mol Genet (2020) |
Reported Trait: Cutaneous melanoma in multiplex melanoma families | — | — | Difference of PRS (deltaPRS; unaffected melanoma family members vs. unrelated controls): 0.347 (0.104) | PCs (1-10) | *Sample overlap between the controls used in this analysis and score development |
PPM000921 | PGS000339 (PRS22_CM) |
PSS000463| European Ancestry| 3,066 individuals |
PGP000106 | Law MH et al. Hum Mol Genet (2020) |
Reported Trait: Cutaneous melanoma in multiplex melanoma families | — | — | Difference of PRS (deltaPRS; melanoma family cases vs. unrelated controls): 0.505 (0.036) | PCs (1-10) | *Sample overlap between the controls used in this analysis and score development |
PPM001083 | PGS000398 (PRSWEB_PHECODE172_20001-1003_PRS-CS_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.042 [1.003, 1.082] β: 0.0407 (0.0195) |
AUROC: 0.51 [0.499, 0.521] | Nagelkerke's Pseudo-R²: 0.00028 Brier score: 0.148 Odds Ratio (OR, top 1% vs. Rest): 1.7 [1.22, 2.38] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_20001-1003_PRS-CS_MGI_20200608 |
PPM001084 | PGS000399 (PRSWEB_PHECODE172_20001-1003_PT_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.158 [1.116, 1.202] β: 0.147 (0.0189) |
AUROC: 0.513 [0.503, 0.523] | Nagelkerke's Pseudo-R²: 0.00545 Brier score: 0.148 Odds Ratio (OR, top 1% vs. Rest): 1.56 [1.12, 2.16] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_20001-1003_PT_MGI_20200608 |
PPM001085 | PGS000400 (PRSWEB_PHECODE172_C3-SKIN_P_5e-08_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.342 [1.291, 1.395] β: 0.294 (0.0197) |
AUROC: 0.581 [0.57, 0.592] | Nagelkerke's Pseudo-R²: 0.0201 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.2 [1.63, 2.98] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_C3-SKIN_P_5e-08_MGI_20200608 |
PPM001086 | PGS000401 (PRSWEB_PHECODE172_C3-SKIN_PRS-CS_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.342 [1.291, 1.396] β: 0.294 (0.0199) |
AUROC: 0.581 [0.57, 0.591] | Nagelkerke's Pseudo-R²: 0.0202 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.25 [1.67, 3.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_C3-SKIN_PRS-CS_MGI_20200608 |
PPM001087 | PGS000402 (PRSWEB_PHECODE172_C3-SKIN_PT_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.366 [1.314, 1.421] β: 0.312 (0.0198) |
AUROC: 0.586 [0.576, 0.597] | Nagelkerke's Pseudo-R²: 0.0224 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.23 [1.64, 3.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_C3-SKIN_PT_MGI_20200608 |
PPM001088 | PGS000403 (PRSWEB_PHECODE172_C3-SKIN_LASSOSUM_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.359 [1.307, 1.413] β: 0.307 (0.0199) |
AUROC: 0.584 [0.573, 0.594] | Nagelkerke's Pseudo-R²: 0.0219 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 1.65 [1.2, 2.27] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_C3-SKIN_LASSOSUM_MGI_20200608 |
PPM001089 | PGS000404 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_P_5e-08_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.369 [1.317, 1.422] β: 0.314 (0.0196) |
AUROC: 0.584 [0.574, 0.594] | Nagelkerke's Pseudo-R²: 0.0226 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.3 [1.72, 3.09] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_P_5e-08_MGI_20200608 |
PPM001090 | PGS000405 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PRS-CS_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.338 [1.287, 1.391] β: 0.291 (0.0199) |
AUROC: 0.58 [0.57, 0.591] | Nagelkerke's Pseudo-R²: 0.0192 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.42 [1.81, 3.24] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PRS-CS_MGI_20200608 |
PPM001091 | PGS000406 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PT_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.392 [1.339, 1.447] β: 0.331 (0.0199) |
AUROC: 0.591 [0.581, 0.602] | Nagelkerke's Pseudo-R²: 0.0249 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.51 [1.89, 3.34] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PT_MGI_20200608 |
PPM001092 | PGS000407 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_LASSOSUM_MGI_20200608) |
PSS000548| European Ancestry| 17,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Skin cancer | OR: 1.38 [1.328, 1.434] β: 0.322 (0.0197) |
AUROC: 0.586 [0.575, 0.597] | Nagelkerke's Pseudo-R²: 0.0245 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.26 [1.69, 3.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_LASSOSUM_MGI_20200608 |
PPM001118 | PGS000433 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_P_5e-08_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.367 [1.31, 1.426] β: 0.312 (0.0215) |
AUROC: 0.584 [0.572, 0.598] | Nagelkerke's Pseudo-R²: 0.0215 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.73 [2.01, 3.72] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C3-OTHER-SKIN_P_5e-08_MGI_20200608 |
PPM001119 | PGS000434 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PRS-CS_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.361 [1.304, 1.42] β: 0.308 (0.0217) |
AUROC: 0.586 [0.573, 0.598] | Nagelkerke's Pseudo-R²: 0.0208 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 1.99 [1.43, 2.78] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PRS-CS_MGI_20200608 |
PPM001120 | PGS000435 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PT_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.357 [1.301, 1.415] β: 0.305 (0.0215) |
AUROC: 0.584 [0.572, 0.597] | Nagelkerke's Pseudo-R²: 0.0201 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.7 [1.99, 3.66] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PT_MGI_20200608 |
PPM001121 | PGS000436 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_LASSOSUM_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.361 [1.305, 1.42] β: 0.308 (0.0216) |
AUROC: 0.584 [0.571, 0.596] | Nagelkerke's Pseudo-R²: 0.021 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.22 [1.61, 3.06] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C3-OTHER-SKIN_LASSOSUM_MGI_20200608 |
PPM001122 | PGS000437 (PRSWEB_PHECODE172.2_C44_P_5e-08_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.352 [1.296, 1.409] β: 0.301 (0.0213) |
AUROC: 0.579 [0.566, 0.592] | Nagelkerke's Pseudo-R²: 0.0206 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.21 [1.6, 3.06] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C44_P_5e-08_MGI_20200608 |
PPM001123 | PGS000438 (PRSWEB_PHECODE172.2_C44_PRS-CS_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.31 [1.256, 1.367] β: 0.27 (0.0216) |
AUROC: 0.575 [0.562, 0.587] | Nagelkerke's Pseudo-R²: 0.0162 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 1.79 [1.28, 2.51] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C44_PRS-CS_MGI_20200608 |
PPM001124 | PGS000439 (PRSWEB_PHECODE172.2_C44_PT_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.348 [1.293, 1.407] β: 0.299 (0.0216) |
AUROC: 0.583 [0.57, 0.595] | Nagelkerke's Pseudo-R²: 0.0197 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.17 [1.57, 3.01] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C44_PT_MGI_20200608 |
PPM001125 | PGS000440 (PRSWEB_PHECODE172.2_C44_LASSOSUM_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.351 [1.296, 1.409] β: 0.301 (0.0215) |
AUROC: 0.581 [0.569, 0.592] | Nagelkerke's Pseudo-R²: 0.0201 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.55 [1.87, 3.46] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C44_LASSOSUM_MGI_20200608 |
PPM001126 | PGS000441 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_P_5e-08_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.39 [1.333, 1.449] β: 0.329 (0.0214) |
AUROC: 0.586 [0.574, 0.599] | Nagelkerke's Pseudo-R²: 0.0241 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.65 [1.94, 3.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_P_5e-08_MGI_20200608 |
PPM001127 | PGS000442 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PRS-CS_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.357 [1.301, 1.417] β: 0.306 (0.0217) |
AUROC: 0.584 [0.572, 0.595] | Nagelkerke's Pseudo-R²: 0.0201 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.35 [1.71, 3.22] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PRS-CS_MGI_20200608 |
PPM001128 | PGS000443 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PT_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.41 [1.352, 1.471] β: 0.344 (0.0216) |
AUROC: 0.591 [0.579, 0.603] | Nagelkerke's Pseudo-R²: 0.0259 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.89 [2.14, 3.92] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PT_MGI_20200608 |
PPM001129 | PGS000444 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_LASSOSUM_MGI_20200608) |
PSS000546| European Ancestry| 15,898 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.399 [1.341, 1.46] β: 0.336 (0.0216) |
AUROC: 0.59 [0.578, 0.601] | Nagelkerke's Pseudo-R²: 0.025 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 3.5 [2.63, 4.65] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_LASSOSUM_MGI_20200608 |
PPM001130 | PGS000445 (PRSWEB_PHECODE172.21_20001-1061_P_5e-08_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.334 [1.264, 1.409] β: 0.289 (0.0278) |
AUROC: 0.571 [0.555, 0.587] | Nagelkerke's Pseudo-R²: 0.0184 Brier score: 0.108 Odds Ratio (OR, top 1% vs. Rest): 2.54 [1.72, 3.74] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1061_P_5e-08_MGI_20200608 |
PPM001131 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.291 [1.221, 1.366] β: 0.256 (0.0286) |
AUROC: 0.575 [0.559, 0.591] | Nagelkerke's Pseudo-R²: 0.0139 Brier score: 0.109 Odds Ratio (OR, top 1% vs. Rest): 1.42 [0.871, 2.33] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608 |
PPM018452 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Skin colour | β: -0.02375 | — | R²: 0.01374 | — | — |
PPM018453 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Freckles | β: 0.04205 | — | R²: 0.02091 | — | — |
PPM018454 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Ease suntan | β: -0.0266 | — | R²: 0.01362 | — | — |
PPM018455 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Ease sunburn | β: 0.04289 | — | R²: 0.01118 | — | — |
PPM018456 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Phototype score | β: -0.62656 | — | R²: 0.03377 | — | — |
PPM018457 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Fitzpatrick scale | β: -0.02673 | — | R²: 0.0294 | — | — |
PPM018458 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Red hair | β: 1.77173 | — | R²: 0.05421 pseudo R²: 0.05421 |
— | — |
PPM001132 | PGS000447 (PRSWEB_PHECODE172.21_20001-1061_PT_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.398 [1.322, 1.477] β: 0.335 (0.0282) |
AUROC: 0.591 [0.575, 0.607] | Nagelkerke's Pseudo-R²: 0.0237 Brier score: 0.108 Odds Ratio (OR, top 1% vs. Rest): 2.5 [1.68, 3.71] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1061_PT_MGI_20200608 |
PPM001133 | PGS000448 (PRSWEB_PHECODE172.21_20001-1061_LASSOSUM_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.411 [1.335, 1.491] β: 0.344 (0.0282) |
AUROC: 0.587 [0.57, 0.604] | Nagelkerke's Pseudo-R²: 0.0254 Brier score: 0.108 Odds Ratio (OR, top 1% vs. Rest): 2.93 [2.03, 4.25] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1061_LASSOSUM_MGI_20200608 |
PPM001134 | PGS000449 (PRSWEB_PHECODE172.21_20001-1073_PRS-CS_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.093 [1.034, 1.155] β: 0.0888 (0.0282) |
AUROC: 0.525 [0.509, 0.54] | Nagelkerke's Pseudo-R²: 0.00141 Brier score: 0.109 Odds Ratio (OR, top 1% vs. Rest): 1.65 [1.04, 2.61] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1073_PRS-CS_MGI_20200608 |
PPM001135 | PGS000450 (PRSWEB_PHECODE172.21_20001-1073_PT_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.079 [1.022, 1.139] β: 0.0759 (0.0278) |
AUROC: 0.504 [0.489, 0.52] | Nagelkerke's Pseudo-R²: 0.00145 Brier score: 0.109 Odds Ratio (OR, top 1% vs. Rest): 1.42 [0.882, 2.3] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1073_PT_MGI_20200608 |
PPM001136 | PGS000451 (PRSWEB_PHECODE172.21_20001-1073_LASSOSUM_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.144 [1.084, 1.208] β: 0.135 (0.0278) |
AUROC: 0.521 [0.506, 0.536] | Nagelkerke's Pseudo-R²: 0.00396 Brier score: 0.109 Odds Ratio (OR, top 1% vs. Rest): 2.44 [1.65, 3.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1073_LASSOSUM_MGI_20200608 |
PPM001137 | PGS000452 (PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.663 [1.57, 1.761] β: 0.508 (0.0293) |
AUROC: 0.632 [0.616, 0.647] | Nagelkerke's Pseudo-R²: 0.0487 Brier score: 0.106 Odds Ratio (OR, top 1% vs. Rest): 3.61 [2.53, 5.15] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_MGI_20200608 |
PPM001138 | PGS000453 (PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_UKB_20200608) |
PSS000568| European Ancestry| 60,018 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.511 [1.47, 1.554] β: 0.413 (0.0142) |
AUROC: 0.611 [0.604, 0.619] | Nagelkerke's Pseudo-R²: 0.0301 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 2.8 [2.33, 3.36] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_UKB_20200608 |
PPM001139 | PGS000454 (PRSWEB_PHECODE172.21_BCC-Chahal_PT_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.661 [1.568, 1.759] β: 0.507 (0.0293) |
AUROC: 0.632 [0.616, 0.647] | Nagelkerke's Pseudo-R²: 0.0489 Brier score: 0.106 Odds Ratio (OR, top 1% vs. Rest): 3.79 [2.68, 5.35] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_BCC-Chahal_PT_MGI_20200608 |
PPM001140 | PGS000455 (PRSWEB_PHECODE172.21_BCC-Chahal_PT_UKB_20200608) |
PSS000568| European Ancestry| 60,018 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.511 [1.47, 1.554] β: 0.413 (0.0142) |
AUROC: 0.611 [0.604, 0.619] | Nagelkerke's Pseudo-R²: 0.0301 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 2.8 [2.33, 3.36] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_BCC-Chahal_PT_UKB_20200608 |
PPM001141 | PGS000456 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.633 [1.541, 1.729] β: 0.49 (0.0293) |
AUROC: 0.63 [0.615, 0.646] | Nagelkerke's Pseudo-R²: 0.0456 Brier score: 0.106 Odds Ratio (OR, top 1% vs. Rest): 3.95 [2.79, 5.58] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_MGI_20200608 |
PPM001142 | PGS000457 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_UKB_20200608) |
PSS000568| European Ancestry| 60,018 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.535 [1.493, 1.579] β: 0.429 (0.0144) |
AUROC: 0.617 [0.609, 0.625] | Nagelkerke's Pseudo-R²: 0.0322 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 3.11 [2.6, 3.71] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_UKB_20200608 |
PPM001143 | PGS000458 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_MGI_20200608) |
PSS000544| European Ancestry| 11,322 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.634 [1.542, 1.732] β: 0.491 (0.0296) |
AUROC: 0.628 [0.612, 0.644] | Nagelkerke's Pseudo-R²: 0.0457 Brier score: 0.106 Odds Ratio (OR, top 1% vs. Rest): 4.03 [2.86, 5.69] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_MGI_20200608 |
PPM001144 | PGS000459 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_UKB_20200608) |
PSS000568| European Ancestry| 60,018 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.528 [1.485, 1.572] β: 0.424 (0.0144) |
AUROC: 0.615 [0.608, 0.623] | Nagelkerke's Pseudo-R²: 0.0314 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 3.05 [2.55, 3.64] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_UKB_20200608 |
PPM001154 | PGS000469 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PRS-CS_MGI_20200608) |
PSS000547| European Ancestry| 5,500 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Carcinoma in situ of skin | OR: 1.09 [1.001, 1.188] β: 0.0865 (0.0437) |
AUROC: 0.524 [0.499, 0.549] | Nagelkerke's Pseudo-R²: 0.00141 Brier score: 0.0939 Odds Ratio (OR, top 1% vs. Rest): 1.48 [0.703, 3.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PRS-CS_MGI_20200608 |
PPM001155 | PGS000470 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PT_MGI_20200608) |
PSS000547| European Ancestry| 5,500 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Carcinoma in situ of skin | OR: 1.308 [1.208, 1.417] β: 0.269 (0.0407) |
AUROC: 0.557 [0.531, 0.582] | Nagelkerke's Pseudo-R²: 0.0154 Brier score: 0.093 Odds Ratio (OR, top 1% vs. Rest): 2.45 [1.34, 4.45] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PT_MGI_20200608 |
PPM001156 | PGS000471 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_LASSOSUM_MGI_20200608) |
PSS000547| European Ancestry| 5,500 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Carcinoma in situ of skin | OR: 1.401 [1.297, 1.513] β: 0.337 (0.0393) |
AUROC: 0.569 [0.541, 0.595] | Nagelkerke's Pseudo-R²: 0.0255 Brier score: 0.0923 Odds Ratio (OR, top 1% vs. Rest): 3.77 [2.24, 6.34] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_LASSOSUM_MGI_20200608 |
PPM001670 | PGS000730 (PRS_BCC) |
PSS000871| European Ancestry| 88,924 individuals |
PGP000138 | Fontanillas P et al. Nat Commun (2021) |
Reported Trait: Basal cell carcinoma | OR: 1.57 [1.55, 1.6] | AUROC: 0.624 | — | — | — |
PPM001963 | PGS000766 (PRS56_CM) |
PSS000982| European Ancestry| 12,712 individuals |
PGP000172 | Bakshi A et al. J Natl Cancer Inst (2021) |
Reported Trait: Incident cutaneous melanoma | — | — | Hazard Ratio (HR, top 20% vs bottom 20%): 2.51 [1.28, 4.92] | — | Only 55 of the 56 SNPs within the PGS were utilised. Rs16891982 was not included as the SNP did not pass imputation quality control. |
PPM001964 | PGS000766 (PRS56_CM) |
PSS000982| European Ancestry| 12,712 individuals |
PGP000172 | Bakshi A et al. J Natl Cancer Inst (2021) |
Reported Trait: Incident cutaneous melanoma (males) | — | — | Hazard Ratio (HR, top 20% vs bottom 20%): 3.7 [1.37, 9.98] | — | Only 55 of the 56 SNPs within the PGS were utilised. Rs16891982 was not included as the SNP did not pass imputation quality control. |
PPM001965 | PGS000766 (PRS56_CM) |
PSS000982| European Ancestry| 12,712 individuals |
PGP000172 | Bakshi A et al. J Natl Cancer Inst (2021) |
Reported Trait: Incident cutaneous melanoma (males) | — | — | Hazard Ratio (HR, middle 60% vs bottom 20%): 2.61 [1.03, 6.63] | — | Only 55 of the 56 SNPs within the PGS were utilised. Rs16891982 was not included as the SNP did not pass imputation quality control. |
PPM001966 | PGS000766 (PRS56_CM) |
PSS000982| European Ancestry| 12,712 individuals |
PGP000172 | Bakshi A et al. J Natl Cancer Inst (2021) |
Reported Trait: Prevalent cutaneous melanoma | OR: 1.55 [1.42, 1.69] | AUROC: 0.64 [0.62, 0.66] | Odds Ratio (OR, top 20% vs bottom 20%): 3.66 [2.69, 5.05] | Sex, family history | Only 55 of the 56 SNPs within the PGS were utilised. Rs16891982 was not included as the SNP did not pass imputation quality control. |
PPM001967 | PGS000766 (PRS56_CM) |
PSS000982| European Ancestry| 12,712 individuals |
PGP000172 | Bakshi A et al. J Natl Cancer Inst (2021) |
Reported Trait: Prevalent cutaneous melanoma (males) | OR: 1.39 [1.23, 1.57] | — | — | Family history | Only 55 of the 56 SNPs within the PGS were utilised. Rs16891982 was not included as the SNP did not pass imputation quality control. |
PPM001968 | PGS000766 (PRS56_CM) |
PSS000982| European Ancestry| 12,712 individuals |
PGP000172 | Bakshi A et al. J Natl Cancer Inst (2021) |
Reported Trait: Prevalent cutaneous melanoma (females) | OR: 1.72 [1.53, 1.94] | — | — | Family history | Only 55 of the 56 SNPs within the PGS were utilised. Rs16891982 was not included as the SNP did not pass imputation quality control. |
PPM001962 | PGS000766 (PRS56_CM) |
PSS000982| European Ancestry| 12,712 individuals |
PGP000172 | Bakshi A et al. J Natl Cancer Inst (2021) |
Reported Trait: Incident cutaneous melanoma | HR: 1.46 [1.2, 1.77] | C-index: 0.643 [0.584, 0.702] | — | Sex, melanoma family history, treatment (aspirin/placebo), age at enrolment, PRS*treatment | Only 55 of the 56 SNPs within the PGS were utilised. Rs16891982 was not included as the SNP did not pass imputation quality control. |
PPM007958 | PGS001040 (GBE_cancer1060) |
PSS007651| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Non-melanoma skin cancer | — | AUROC: 0.80478 [0.72556, 0.884] | R²: 0.07029 Incremental AUROC (full-covars): -0.00066 PGS R2 (no covariates): 0.00133 PGS AUROC (no covariates): 0.54127 [0.39017, 0.69237] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM007959 | PGS001040 (GBE_cancer1060) |
PSS007652| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Non-melanoma skin cancer | — | AUROC: 0.86455 [0.80574, 0.92335] | R²: 0.12918 Incremental AUROC (full-covars): -0.00442 PGS R2 (no covariates): 0.00152 PGS AUROC (no covariates): 0.4523 [0.1694, 0.73519] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM007960 | PGS001040 (GBE_cancer1060) |
PSS007653| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Non-melanoma skin cancer | — | AUROC: 0.73342 [0.72065, 0.74619] | R²: 0.10751 Incremental AUROC (full-covars): 0.0378 PGS R2 (no covariates): 0.05185 PGS AUROC (no covariates): 0.66327 [0.64889, 0.67765] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM007961 | PGS001040 (GBE_cancer1060) |
PSS007654| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Non-melanoma skin cancer | — | AUROC: 0.76366 [0.66832, 0.85901] | R²: 0.06447 Incremental AUROC (full-covars): -0.00934 PGS R2 (no covariates): 0.00078 PGS AUROC (no covariates): 0.47181 [0.35611, 0.58752] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM007962 | PGS001040 (GBE_cancer1060) |
PSS007655| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Non-melanoma skin cancer | — | AUROC: 0.70656 [0.69863, 0.7145] | R²: 0.08615 Incremental AUROC (full-covars): 0.04717 PGS R2 (no covariates): 0.03949 PGS AUROC (no covariates): 0.64209 [0.6334, 0.65078] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM018463 | PGS001040 (GBE_cancer1060) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Ease sunburn | β: 0.08836 | — | R²: 0.01475 | — | — |
PPM018465 | PGS001040 (GBE_cancer1060) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Fitzpatrick scale | β: -0.0689 | — | R²: 0.03786 | — | — |
PPM018459 | PGS001040 (GBE_cancer1060) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Eye colour | β: -0.11302 | — | R²: 0.0106 | — | — |
PPM018460 | PGS001040 (GBE_cancer1060) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Skin colour | β: -0.05462 | — | R²: 0.01757 | — | — |
PPM018461 | PGS001040 (GBE_cancer1060) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Freckles | β: 0.09955 | — | R²: 0.02643 | — | — |
PPM018462 | PGS001040 (GBE_cancer1060) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Ease suntan | β: -0.06804 | — | R²: 0.01892 | — | — |
PPM018464 | PGS001040 (GBE_cancer1060) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Phototype score | β: -1.51455 | — | R²: 0.04441 | — | — |
PPM018466 | PGS001040 (GBE_cancer1060) |
PSS010980| European Ancestry| 4,797 individuals |
PGP000467 | Farré X et al. Genes (Basel) (2023) |Ext. |
Reported Trait: Blond hair | β: 1.14835 | — | pseudo R²: 0.01006 | — | — |
PPM007963 | PGS001041 (GBE_cancer1003) |
PSS007621| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Skin cancer | — | AUROC: 0.78777 [0.7126, 0.86293] | R²: 0.06151 Incremental AUROC (full-covars): 0.00386 PGS R2 (no covariates): 0.00103 PGS AUROC (no covariates): 0.5229 [0.37426, 0.67153] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM007964 | PGS001041 (GBE_cancer1003) |
PSS007622| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Skin cancer | — | AUROC: 0.83061 [0.75233, 0.9089] | R²: 0.10839 Incremental AUROC (full-covars): 0.0017 PGS R2 (no covariates): 0.00376 PGS AUROC (no covariates): 0.56985 [0.36492, 0.77477] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM007965 | PGS001041 (GBE_cancer1003) |
PSS007623| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Skin cancer | — | AUROC: 0.71667 [0.70431, 0.72902] | R²: 0.09613 Incremental AUROC (full-covars): 0.03439 PGS R2 (no covariates): 0.04566 PGS AUROC (no covariates): 0.65086 [0.63722, 0.6645] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM007966 | PGS001041 (GBE_cancer1003) |
PSS007624| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Skin cancer | — | AUROC: 0.76232 [0.67332, 0.85131] | R²: 0.07091 Incremental AUROC (full-covars): -0.01012 PGS R2 (no covariates): 6e-05 PGS AUROC (no covariates): 0.49291 [0.37897, 0.60686] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM007967 | PGS001041 (GBE_cancer1003) |
PSS007625| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Skin cancer | — | AUROC: 0.6935 [0.68584, 0.70116] | R²: 0.07834 Incremental AUROC (full-covars): 0.04393 PGS R2 (no covariates): 0.03573 PGS AUROC (no covariates): 0.63289 [0.62459, 0.64118] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM009332 | PGS001803 (portability-PLR_172) |
PSS008601| European Ancestry| 6,656 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.0762 [0.0522, 0.1001] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009333 | PGS001803 (portability-PLR_172) |
PSS008379| Greater Middle Eastern Ancestry| 1,200 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.0694 [0.0123, 0.1259] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009334 | PGS001803 (portability-PLR_172) |
PSS008155| South Asian Ancestry| 6,328 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): -0.0135 [-0.0382, 0.0112] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009330 | PGS001803 (portability-PLR_172) |
PSS009273| European Ancestry| 19,990 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.1136 [0.0999, 0.1272] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009331 | PGS001803 (portability-PLR_172) |
PSS009047| European Ancestry| 4,134 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.0962 [0.0659, 0.1264] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009335 | PGS001803 (portability-PLR_172) |
PSS007943| East Asian Ancestry| 1,810 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.0054 [-0.041, 0.0517] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009336 | PGS001803 (portability-PLR_172) |
PSS007725| African Ancestry| 2,483 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): -0.0065 [-0.046, 0.033] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009337 | PGS001803 (portability-PLR_172) |
PSS008827| African Ancestry| 3,924 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.0165 [-0.0149, 0.0479] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM010986 | PGS002014 (portability-ldpred2_172) |
PSS009273| European Ancestry| 19,990 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.1242 [0.1105, 0.1378] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM010990 | PGS002014 (portability-ldpred2_172) |
PSS008155| South Asian Ancestry| 6,328 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): -0.0147 [-0.0394, 0.01] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM010991 | PGS002014 (portability-ldpred2_172) |
PSS007943| East Asian Ancestry| 1,810 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): -0.0041 [-0.0504, 0.0423] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM010992 | PGS002014 (portability-ldpred2_172) |
PSS007725| African Ancestry| 2,483 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): -0.0062 [-0.0457, 0.0333] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM010993 | PGS002014 (portability-ldpred2_172) |
PSS008827| African Ancestry| 3,924 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.0146 [-0.0168, 0.0459] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM010987 | PGS002014 (portability-ldpred2_172) |
PSS009047| European Ancestry| 4,134 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.0876 [0.0572, 0.1178] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM010988 | PGS002014 (portability-ldpred2_172) |
PSS008601| European Ancestry| 6,656 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.076 [0.0521, 0.0999] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM010989 | PGS002014 (portability-ldpred2_172) |
PSS008379| Greater Middle Eastern Ancestry| 1,200 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Skin cancer | — | — | Partial Correlation (partial-r): 0.0717 [0.0147, 0.1282] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM016257 | PGS003382 (best_SKCM) |
PSS010085| European Ancestry| 273,786 individuals |
PGP000413 | Namba S et al. Cancer Res (2022) |
Reported Trait: skin cutaneous melanoma | — | AUROC: 0.682 | R²: 0.0261 | age, sex, top 20 genetic principal components | — |
PPM017069 | PGS003416 (MTAGPRS) |
PSS010113| European Ancestry| 18,933 individuals |
PGP000429 | Seviiri M et al. Nat Commun (2022) |
Reported Trait: Keratinocyte cancers | OR: 1.66 [1.55, 1.79] | — | — | age, sex, 10 ancesty PCs | — |
PPM017070 | PGS003417 (UKBPRS) |
PSS010113| European Ancestry| 18,933 individuals |
PGP000429 | Seviiri M et al. Nat Commun (2022) |
Reported Trait: Keratinocyte cancers | OR: 1.56 [1.45, 1.67] | — | — | age, sex, 10 ancesty PCs | — |
PPM018501 | PGS003745 (PRS57_SM) |
PSS010995| European Ancestry| 448 individuals |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Reported Trait: Skin Melanoma | OR: 1.49 [1.34, 1.66] | — | — | — | — |
PPM020312 | PGS004247 (PRS65_melanoma) |
PSS011329| European Ancestry| 115,207 individuals |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Reported Trait: Melanoma | HR: 1.71 [1.55, 1.89] | — | — | first 10 genetic principal components | — |
PPM020304 | PGS004247 (PRS65_melanoma) |
PSS011328| European Ancestry| 133,830 individuals |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Reported Trait: Melanoma | HR: 1.78 [1.62, 1.96] | — | — | first 10 genetic principal components | — |
PPM020722 | PGS004592 (PRS_KC) |
PSS011383| European Ancestry| 998 individuals |
PGP000571 | Liyanage UE et al. J Eur Acad Dermatol Venereol (2022) |
Reported Trait: Keratinocyte cancer | OR: 1.51 [1.3, 1.76] | AUROC: 0.74 | R²: 0.231 | Age, sex, self-reported skin tanning ability, clinical grade of neck elastosis, genotyping batch, first 2 PCs | — |
PPM020723 | PGS004592 (PRS_KC) |
PSS011383| European Ancestry| 998 individuals |
PGP000571 | Liyanage UE et al. J Eur Acad Dermatol Venereol (2022) |
Reported Trait: Keratinocyte cancer | — | — | Odds ratio (OR, top PRS quintile vs bottom PRS quintile): 3.45 [2.18, 5.5] | Age, sex, self-reported skin tanning ability, clinical grade of neck elastosis, genotyping batch, first 2 PCs | — |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS007621 | — | — | [
|
— | African unspecified | — | UKB | — |
PSS007622 | — | — | [
|
— | East Asian | — | UKB | — |
PSS007623 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
PSS007624 | — | — | [
|
— | South Asian | — | UKB | — |
PSS007625 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
PSS000568 | PheCode:172.21; ICD9:173, 173.0, 173.1, 173.2, 173.3, 173.4, 173.5, 173.6, 173.7, 173.8, 173.9; ICD10:C44.0, C44.1, C44.2, C44.3, C44.4, C44.5, C44.6, C44.7, C44.8, C44.9 | — | [
|
— | European | — | UKB | — |
PSS011383 | — | — | [ ,
44.0 % Male samples |
— | European | — | NSCS | — |
PSS011328 | — | — | 133,830 individuals, 0.0 % Male samples |
— | European (British) |
— | UKB | — |
PSS011329 | — | — | 115,207 individuals, 100.0 % Male samples |
— | European (British) |
— | UKB | — |
PSS009047 | — | — | 4,134 individuals | — | European | Poland (NE Europe) | UKB | — |
PSS008155 | — | — | 6,328 individuals | — | South Asian | India (South Asia) | UKB | — |
PSS010113 | — | — | 18,933 individuals | — | European | — | CLSA | — |
PSS010995 | — | — | 448 individuals | Mean = 58.23 years | European | — | TCGA | — |
PSS000463 | Unaffected family members from families with increased melaona risk. Recruited families were ranked as low-, medium- or high-risk using a risk index (T) that factored in the number of confirmed cases of melanoma versus number of unaffected family members, ages and year of birth | — | [ ,
46.28 % Male samples |
— | European | Australia | BATS, QFMP | — |
PSS000464 | Unaffected family members from families with increased melaona risk. Recruited families were ranked as low-, medium- or high-risk using a risk index (T) that factored in the number of confirmed cases of melanoma versus number of unaffected family members, ages and year of birth | — | [ ,
46.37 % Male samples |
— | European | Australia | BATS, QFMP | — |
PSS000207 | PheCode 172 | — | [ ,
46.9 % Male samples |
Mean = 54.2 years Sd = 15.9 years |
European | — | MGI | — |
PSS000209 | Basal cell carcinoma: ICD9-173.01,173.11,173.21,173.31,173.41,173.51,173.61,173.71,173.81,173.91 | — | [ ,
46.9 % Male samples |
Mean = 54.2 years Sd = 15.9 years |
European | — | MGI | — |
PSS000211 | PheCode 172 | — | [ ,
45.9 % Male samples |
Mean = 57.7 years Sd = 8.1 years |
European | White British Subset | UKB | — |
PSS007651 | — | — | [
|
— | African unspecified | — | UKB | — |
PSS007652 | — | — | [
|
— | East Asian | — | UKB | — |
PSS007653 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
PSS007654 | — | — | [
|
— | South Asian | — | UKB | — |
PSS007655 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
PSS008827 | — | — | 3,924 individuals | — | African unspecified | Nigeria (West Africa) | UKB | — |
PSS007943 | — | — | 1,810 individuals | — | East Asian | China (East Asia) | UKB | — |
PSS008601 | — | — | 6,656 individuals | — | European | Italy (South Europe) | UKB | — |
PSS010085 | C43 | — | [
|
— | European (British) |
— | UKB | Controls were samples without any cancer diagnosis or self-reported cancer |
PSS000982 | Cases were individuals with cutaneous melanoma. Of the 628 cases, 528 were prevalent melanoma, whilst 98 were incident melanoma cases. Endpoints used were primary invasive cutaneous melanoma and metastatic melanoma with unknown primary location occurring during the trial (incident). Metastatic recurrence was excluded. Incident melanomas were confirmed by expert panel using histopathology, imaging of metastasis or other clinical evidence. If a participant had two events during the trial, the time of the first event was used. Prevalent melanomas occurring pre-trial were self-reported by participants but not confirmed by review of medical records and assumed to be invasive. Age at diagnosis for self-reported melanomas was reported as either before or after 50 years. | Median = 4.7 years | [ ,
45.0 % Male samples |
Mean = 75.0 years Sd = 4.23 years |
European | — | ASPREE | — |
PSS010980 | — | — | 4,797 individuals | — | European | — | NR | GCAT |
PSS000871 | Basal cell carcinoma cases were determined by a baseline survey containing 34 questions regarding personal history of skin cancer(including skin cancer type, age at diagnosis, body location, prescribed treatments and information regarding cancer recurrence) | — | [ ,
38.9 % Male samples |
European | — | 23andMe | — | |
PSS007725 | — | — | 2,483 individuals | — | African American or Afro-Caribbean | Carribean | UKB | — |
PSS009273 | — | — | 19,990 individuals | — | European | UK (+ Ireland) | UKB | — |
PSS000544 | PheCode:172.21; ICD9CM:173.01, 173.11, 173.21, 173.31, 173.41, 173.51, 173.61, 173.71, 173.81, 173.91; ICD10CM:C44.01, C44.111, C44.112, C44.119, C44.211, C44.212, C44.219, C44.310, C44.311, C44.319, C44.41, C44.510, C44.511, C44.519, C44.611, C44.612, C44.619, C44.711, C44.712, C44.719, C44.81, C44.91 | — | [
|
— | European | — | MGI | — |
PSS008379 | — | — | 1,200 individuals | — | Greater Middle Eastern (Middle Eastern, North African or Persian) | Iran (Middle East) | UKB | — |
PSS000546 | PheCode:172.2; ICD9CM:173.00, 173.01, 173.02, 173.09, 173.10, 173.11, 173.12, 173.19, 173.20, 173.21, 173.22, 173.29, 173.30, 173.31, 173.32, 173.39, 173.40, 173.41, 173.42, 173.49, 173.50, 173.51, 173.52, 173.59, 173.60, 173.61, 173.62, 173.69, 173.70, 173.71, 173.72, 173.79, 173.80, 173.81, 173.82, 173.89, 173.90, 173.91, 173.92, 173.99, 209.31, 209.32, 209.33, 209.34, 209.35, 209.36, V10.83; ICD10CM:C44.0, C44.00, C44.01, C44.02, C44.09, C44.1, C44.10, C44.101, C44.102, C44.109, C44.11, C44.111, C44.112, C44.119, C44.12, C44.121, C44.122, C44.129, C44.19, C44.191, C44.192, C44.199, C44.2, C44.20, C44.201, C44.202, C44.209, C44.21, C44.211, C44.212, C44.219, C44.22, C44.221, C44.222, C44.229, C44.29, C44.291, C44.292, C44.299, C44.30, C44.300, C44.301, C44.309, C44.31, C44.310, C44.311, C44.319, C44.320, C44.321, C44.329, C44.39, C44.390, C44.391, C44.399, C44.4, C44.40, C44.41, C44.42, C44.49, C44.500, C44.501, C44.509, C44.51, C44.510, C44.511, C44.519, C44.52, C44.520, C44.521, C44.529, C44.59, C44.590, C44.591, C44.599, C44.6, C44.60, C44.601, C44.602, C44.609, C44.61, C44.611, C44.612, C44.619, C44.62, C44.621, C44.622, C44.629, C44.69, C44.691, C44.692, C44.699, C44.7, C44.70, C44.701, C44.702, C44.709, C44.71, C44.711, C44.712, C44.719, C44.72, C44.721, C44.722, C44.729, C44.79, C44.791, C44.792, C44.799, C44.8, C44.80, C44.81, C44.82, C44.89, C44.9, C44.90, C44.91, C44.92, C44.99, C4A, C4A.0, C4A.1, C4A.10, C4A.11, C4A.12, C4A.2, C4A.20, C4A.21, C4A.22, C4A.3, C4A.30, C4A.31, C4A.39, C4A.4, C4A.5, C4A.51, C4A.52, C4A.59, C4A.6, C4A.60, C4A.61, C4A.62, C4A.7, C4A.70, C4A.71, C4A.72, C4A.8, C4A.9 | — | [
|
— | European | — | MGI | — |
PSS000547 | PheCode:172.3; ICD9CM:232.0, 232.1, 232.2, 232.3, 232.4, 232.5, 232.6, 232.7, 232.8, 232.9; ICD10CM:D04, D04.0, D04.1, D04.10, D04.11, D04.12, D04.2, D04.20, D04.21, D04.22, D04.3, D04.30, D04.39, D04.4, D04.5, D04.6, D04.60, D04.61, D04.62, D04.7, D04.70, D04.71, D04.72, D04.8, D04.9 | — | [
|
— | European | — | MGI | — |
PSS000548 | PheCode:172; ICD9CM:172.0, 172.1, 172.2, 172.3, 172.4, 172.5, 172.6, 172.7, 172.8, 172.9, 173.00, 173.01, 173.02, 173.09, 173.10, 173.11, 173.12, 173.19, 173.20, 173.21, 173.22, 173.29, 173.30, 173.31, 173.32, 173.39, 173.40, 173.41, 173.42, 173.49, 173.50, 173.51, 173.52, 173.59, 173.60, 173.61, 173.62, 173.69, 173.70, 173.71, 173.72, 173.79, 173.80, 173.81, 173.82, 173.89, 173.90, 173.91, 173.92, 173.99, 209.31, 209.32, 209.33, 209.34, 209.35, 209.36, 232.0, 232.1, 232.2, 232.3, 232.4, 232.5, 232.6, 232.7, 232.8, 232.9, V10.82, V10.83; ICD10CM:C43, C43.0, C43.1, C43.10, C43.11, C43.12, C43.2, C43.20, C43.21, C43.22, C43.3, C43.30, C43.31, C43.39, C43.4, C43.5, C43.51, C43.52, C43.59, C43.6, C43.60, C43.61, C43.62, C43.7, C43.70, C43.71, C43.72, C43.8, C43.9, C44.0, C44.00, C44.01, C44.02, C44.09, C44.1, C44.10, C44.101, C44.102, C44.109, C44.11, C44.111, C44.112, C44.119, C44.12, C44.121, C44.122, C44.129, C44.19, C44.191, C44.192, C44.199, C44.2, C44.20, C44.201, C44.202, C44.209, C44.21, C44.211, C44.212, C44.219, C44.22, C44.221, C44.222, C44.229, C44.29, C44.291, C44.292, C44.299, C44.30, C44.300, C44.301, C44.309, C44.31, C44.310, C44.311, C44.319, C44.320, C44.321, C44.329, C44.39, C44.390, C44.391, C44.399, C44.4, C44.40, C44.41, C44.42, C44.49, C44.500, C44.501, C44.509, C44.51, C44.510, C44.511, C44.519, C44.52, C44.520, C44.521, C44.529, C44.59, C44.590, C44.591, C44.599, C44.6, C44.60, C44.601, C44.602, C44.609, C44.61, C44.611, C44.612, C44.619, C44.62, C44.621, C44.622, C44.629, C44.69, C44.691, C44.692, C44.699, C44.7, C44.70, C44.701, C44.702, C44.709, C44.71, C44.711, C44.712, C44.719, C44.72, C44.721, C44.722, C44.729, C44.79, C44.791, C44.792, C44.799, C44.8, C44.80, C44.81, C44.82, C44.89, C44.9, C44.90, C44.91, C44.92, C44.99, C4A, C4A.0, C4A.1, C4A.10, C4A.11, C4A.12, C4A.2, C4A.20, C4A.21, C4A.22, C4A.3, C4A.30, C4A.31, C4A.39, C4A.4, C4A.5, C4A.51, C4A.52, C4A.59, C4A.6, C4A.60, C4A.61, C4A.62, C4A.7, C4A.70, C4A.71, C4A.72, C4A.8, C4A.9, D03, D03.0, D03.1, D03.10, D03.11, D03.12, D03.2, D03.20, D03.21, D03.22, D03.3, D03.30, D03.39, D03.4, D03.5, D03.51, D03.52, D03.59, D03.6, D03.60, D03.61, D03.62, D03.7, D03.70, D03.71, D03.72, D03.8, D03.9, D04, D04.0, D04.1, D04.10, D04.11, D04.12, D04.2, D04.20, D04.21, D04.22, D04.3, D04.30, D04.39, D04.4, D04.5, D04.6, D04.60, D04.61, D04.62, D04.7, D04.70, D04.71, D04.72, D04.8, D04.9 | — | [
|
— | European | — | MGI | — |